Kadmon Investors and Media

Investors

Press Releases

Press Releases

Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021. "We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA... Read More

Kadmon Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology

NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the Journal of Clinical... Read More

Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis

NEW YORK, NY / ACCESSWIRE / April 1, 2021 /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company's ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic... Read More

Kadmon Announces Trial-In-Progress Poster on KD033 at the 2021 American Association for Cancer Research Annual Meeting

NEW YORK, NY / ACCESSWIRE / March 25, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present a trial-in-progress poster on KD033-101, the Company's ongoing dose-escalation, dose-expansion trial of KD033 in patients with metastatic and locally advanced solid tumors, at the 2021... Read More

Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease

NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD).... Read More

Kadmon Provides Business Update and Reports Fourth Quarter 2020 Financial Results

NEW YORK, NY / ACCESSWIRE / March 4, 2021 /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020 . "With the acceptance of Kadmon's new drug application for belumosudil in... Read More

Kadmon Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper , MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021 . In this role, Dr. Cooper will oversee the Company's medical and clinical activities... Read More

Kadmon to Present at Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / February 24, 2021 /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present and host investor meetings at the following virtual investor conferences: Raymond James 42 nd Annual Institutional... Read More

Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment Option

NEW YORK, NY / ACCESSWIRE / February 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the closing of $240 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private, overnight offering to qualified institutional buyers pursuant to Rule... Read More

Kadmon Announces Pricing of $200 Million Convertible Senior Notes Offering with 100% Capped Call Transactions

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the pricing of $200 million aggregate principal amount of 3.625% convertible senior notes due 2027 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under... Read More
Displaying 1 - 10 of 12